- The Danaher Beacon for Brain Injury Diagnostics seeks to
identify mild Traumatic Brain Injury (TBI) earlier and more
precisely.
- Scientists will evaluate new blood-based biomarkers using
highly sensitive technology from Beckman Coulter Diagnostics.
- This approach could potentially be adapted for diagnosis of
other neurological conditions.
WASHINGTON, May 9, 2024
/PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science
and technology innovator ("Danaher"), today launched a
collaboration with Johns Hopkins
University aiming to develop new methods for diagnosing mild
TBI. As part of the Danaher Beacons program, researchers at
Johns Hopkins University will leverage
technology from Beckman Coulter Diagnostics, a Danaher subsidiary
and leader in clinical diagnostics, to potentially
establish correlations between a new biomarker panel and
clinical outcomes.
Julie Sawyer Montgomery, Vice
President and Group Executive, Danaher
Diagnostics, said: "Our latest in vitro
diagnostics innovations are improving the detection of specific
biomarkers found in blood when brain cells are damaged. We are
thrilled to partner with Johns Hopkins
with the goal of leveraging these solutions to develop tests for
earlier and more precise diagnosis of mild TBI, which could
ultimately lead to improved treatment outcomes and faster recovery
for patients."
Nearly 56 million mild TBI patients worldwide could benefit from
a more precise approach to diagnosis1. While computed
tomography (CT) is used to visualize tissue damage and diagnose
moderate to severe TBI, mild TBI correlates poorly with
abnormalities on head CTs2. Doctors therefore need a
better way to decide which patients should undergo a CT scan and
identify patients who have a higher risk of developing
incapacitating symptoms.
The Beacon builds on recent neurological biomarker
research3 and next-generation immunoassay detection
technology developed by Beckman Coulter Diagnostics. If effective,
the approach could potentially be adapted for the diagnosis of
other types of brain injury or neurodegenerative diseases. The
research will be led by Jessica
Gill, PhD, MSN, BSN, RN, Professor at the Johns Hopkins School of Nursing and Richard Rothman, MD, PhD, Professor of Emergency
Medicine at Johns Hopkins Medicine.
The Danaher Beacon for Brain Injury Diagnostics is the sixth
collaboration in the Danaher Beacons program, which funds
product-driven scientific research with globally recognized
academic investigators.
ABOUT DANAHER
Danaher is a leading global life
sciences and diagnostics innovator, committed to accelerating the
power of science and technology to improve human health. Our
businesses partner closely with customers to solve many of the most
important health challenges impacting patients around the
world. Danaher's advanced science and technology - and proven
ability to innovate - help enable faster, more accurate diagnoses
and help reduce the time and cost needed to sustainably discover,
develop and deliver life-changing therapies. Focused on
scientific excellence, innovation and continuous improvement, our
approximately 63,000 associates worldwide help ensure that Danaher
is improving quality of life for billions of people today, while
setting the foundation for a healthier, more sustainable tomorrow.
Explore more at www.danaher.com.
FORWARD-LOOKING STATEMENTS
Statements in this release
that are not strictly historical, including any statements
regarding events or developments that Danaher believes or
anticipates will or may occur in the future are "forward-looking"
statements within the meaning of the federal securities laws. These
factors include, among other things: unanticipated, further
declines in demand for our COVID-19 related products, the impact of
global health crises, the impact of our debt obligations on our
operations and liquidity, deterioration of or instability in the
global economy, the markets we serve and the financial markets,
uncertainties with respect to the development, deployment, and use
of artificial intelligence in our business and products,
uncertainties relating to national laws or policies, including laws
or policies to protect or promote domestic interests and/or address
foreign competition, contractions or growth rates and cyclicality
of markets we serve, competition, our ability to develop and
successfully market new products and technologies and expand into
new markets, the potential for improper conduct by our employees,
agents or business partners, our compliance with applicable laws
and regulations (including rules relating to off-label marketing
and other regulations relating to medical devices and the health
care industry), the results of our clinical trials and perceptions
thereof, our ability to effectively address cost reductions and
other changes in the health care industry, our ability to
successfully identify and consummate appropriate acquisitions and
strategic investments, our ability to integrate the businesses we
acquire and achieve the anticipated growth, synergies and other
benefits of such acquisitions, contingent liabilities and other
risks relating to acquisitions, investments, strategic
relationships and divestitures (including tax-related and other
contingent liabilities relating to past and future IPOs, split-offs
or spin-offs), security breaches or other disruptions of our
information technology systems or violations of data privacy laws,
the impact of our restructuring activities on our ability to grow,
risks relating to potential impairment of goodwill and other
intangible assets, currency exchange rates, tax audits and changes
in our tax rate and income tax liabilities, changes in tax laws
applicable to multinational companies, litigation and other
contingent liabilities including intellectual property and
environmental, health and safety matters, the rights of the
United States government with respect to our production
capacity in times of national emergency or with respect to
intellectual property/production capacity developed using
government funding, risks relating to product, service or software
defects, product liability and recalls, risks relating to our
manufacturing operations and fluctuations in the cost and
availability of the supplies we use (including commodities) and
labor we need for our operations, our relationships with and the
performance of our channel partners, uncertainties relating to
collaboration arrangements with third-parties, the impact of
deregulation on demand for our products and services, the impact of
climate change, legal or regulatory measures to address climate
change and our ability to address stakeholder expectations relating
to climate change, labor matters and our ability to recruit, retain
and motivate talented employees representing diverse backgrounds,
experiences and skill sets, non-U.S. economic, political, legal,
compliance, social and business factors (including the impact of
military conflicts), disruptions relating to man-made and natural
disasters, inflation and the impact of our By-law exclusive forum
provisions. Additional information regarding the factors that
may cause actual results to differ materially from these
forward-looking statements is available in our SEC filings,
including our 2023 Annual Report on Form 10-K and Quarterly Report
on Form 10-Q for the first quarter of 2024. These
forward-looking statements speak only as of the date of this
release and except to the extent required by applicable law, the
Company does not assume any obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events and developments or otherwise.
Sources
-
https://nap.nationalacademies.org/catalog/25394/traumatic-brain-injury-a-roadmap-for-accelerating-progress
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469272
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359936/
View original
content:https://www.prnewswire.com/news-releases/danaher-launches-collaboration-with-johns-hopkins-university-aiming-to-improve-neurological-diagnosis-302140906.html
SOURCE Danaher Corporation